Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Pet Deal benchmark

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Oct 24, 2022 11:39am

115 Views

Post# 35043753

RE:RE:Pet Deal benchmark

Not neccessarily. The competitors might choose TFC-039 to take on Elanco.

It's not like the Elanco-deal has been unknown until today. Management must have some insight on existing deals - after all, I think Linda Pullan is still active in supporting management even though Howard decides in the end - unfortunately.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market